Latest News for: copd

Edit

Just Cough Into Your Phone: AI App Helps Screen Asthma, COPD In Minutes | Check Details

News18 19 Feb 2026
The app, called Swaasa, was featured as an innovation case study at the International AI Impact Summit 2026, being held at Bharat Mandapam, Delhi ....
Edit

AI app analysing coughs could close COPD diagnostic gaps in primary care, AIIMS study shows

The Times of India 18 Feb 2026
Comments. +Text SizeSmallMediumLarge. .
Edit

GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows (GSK plc)

Public Technologies 17 Feb 2026
... pulmonary disease (COPD) and asthma†2 during RSV-related hospitalisation ... † among US adults aged 60 years and older with existing chronic obstructive pulmonary disease (COPD) and asthma, respectively.
Edit

After Steve got breathless on short walks he was diagnosed with deadly COPD. Now he's ...

The Daily Mail 14 Feb 2026
When Steve Bowen became breathless on a short walk after picking up his grandson Riggs from school, he knew something was seriously wrong. His head was pounding ....
Edit

Fans mourn rock icon dead at 83 after COPD, heart failure battle: ‘Incredible talent’

Penn Live 08 Feb 2026
Chuck Negron, a founding member and frontman for the beloved rock band Three Dog Night, has died. He was 83. Deadline reported that Negron had been battling COPD and was also suffering from heart failure in recent months ... “Always loved his voice ... ....
Edit

Stopping COPD inhalers can lead to higher risk of flare-ups for 3 months (The University of Manchester)

Public Technologies 06 Feb 2026
Stopping COPD inhalers can lead to higher risk of flare-ups for 3 months ... COPD is the name for a group of lung conditions that cause breathing difficulties, including emphysema and chronic bronchitis.
Edit

Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD) (Form 6-K) (GSK plc)

Public Technologies 06 Feb 2026
Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD) ... Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype.
Edit

Natural ways to support lung health amid rising COPD concerns

Natural News 03 Feb 2026
Chronic obstructive pulmonary disease (COPD) caused 3.5 million deaths in 2021 (5% of global fatalities). Conventional treatments (bronchodilators... .
Edit

COPD Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by ...

GetNews 20 Jan 2026
CNTB), a clinical-stage biopharmaceutical company dedicated to advancing treatments for asthma and chronic obstructive pulmonary disease (COPD), has received encouraging feedback from its Type C meeting with the U.S ... for COPD maintenance therapy.
Edit

Worsening Air Quality Fuels Sales Of Asthma, COPD And Allergy Drugs: Data

News18 09 Jan 2026
Asthma, Chronic Obstructive Pulmonary Disease (COPD), allergy and nasal therapies see sustained growth amid severe to very poor AQI in urban centres along with seasonal infections ....
Edit

AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD)

Pharmiweb 09 Jan 2026
“While recent therapeutic advances have given the COPD community new treatment options, we believe there is room for improvement with respect to efficacy and patient experience,” said Maria Fardis, Ph.D., MBA, CEO of AirNexis.
Edit

Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

PR Newswire 06 Jan 2026
The Phase Ib study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BBT002 in COPD as well as other type 2 inflammatory respiratory indications, including asthma and chronic rhinosinusitis with nasal polyps.
Edit

MHRA authorises Nucala (mepolizumab) in the UK for the treatment of uncontrolled COPD of an eosinophilic phenotype for patients on triple therapy*

Pharmiweb 06 Jan 2026
COPD is the name for a ... In placebo-controlled studies in patients with COPD, the most commonly reported adverse reactions during treatment were headache (10%), back pain (7%) and arthralgia (5%).[xi].
Edit

Pneumonia, COPD cases rise at pvt hosps

The Times of India 05 Jan 2026
+Text SizeSmallMediumLarge. .
Edit

Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD) (Form 6-K) (GSK plc)

Public Technologies 05 Jan 2026
Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD) ... Mepolizumab is the first and only monthly biologic approved in China and evaluated in COPD patients with a BEC starting as low as 150 cells/µL.

Article Search

tools
×
×
×
×